High Expression of MORC2 is Associated with Poor Clinical Outcomes and Immune Infiltrates in Colon Adenocarcinoma
Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated. Methods: The cli...
Saved in:
Published in | International journal of general medicine Vol. 16; pp. 4595 - 4615 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Dove Medical Press Limited
31.10.2023
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
ISSN | 1178-7074 1178-7074 |
DOI | 10.2147/IJGM.S420715 |
Cover
Loading…
Abstract | Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated. Methods: The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan--Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3). Results: MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on. Conclusion: The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients. Keywords: MORC2, colon adenocarcinoma, diagnosis, prognosis, immune cell infiltration, biomarker |
---|---|
AbstractList | Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated.PurposeMicrorchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated.The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan-Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3).MethodsThe clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan-Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3).MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on.ResultsMORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on.The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients.ConclusionThe findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients. Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated. Methods: The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan--Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3). Results: MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on. Conclusion: The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients. Keywords: MORC2, colon adenocarcinoma, diagnosis, prognosis, immune cell infiltration, biomarker Peizhuang Zhao,* Jiajia Ning,* Jun Huang,* Binqian Wei, Zhen Wang, Xue Huang Department of Geriatrics and Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xue Huang, Department of Geriatrics and Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530000, People’s Republic of China, Email hb960305@163.comPurpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated.Methods: The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan–Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3).Results: MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on.Conclusion: The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients.Keywords: MORC2, colon adenocarcinoma, diagnosis, prognosis, immune cell infiltration, biomarker |
Audience | Academic |
Author | Wei, Binqian Zhao, Peizhuang Huang, Xue Ning, Jiajia Huang, Jun Wang, Zhen |
Author_xml | – sequence: 1 givenname: Peizhuang surname: Zhao fullname: Zhao, Peizhuang – sequence: 2 givenname: Jiajia surname: Ning fullname: Ning, Jiajia – sequence: 3 givenname: Jun surname: Huang fullname: Huang, Jun – sequence: 4 givenname: Binqian surname: Wei fullname: Wei, Binqian – sequence: 5 givenname: Zhen surname: Wang fullname: Wang, Zhen – sequence: 6 givenname: Xue orcidid: 0000-0002-3034-1848 surname: Huang fullname: Huang, Xue |
BookMark | eNptkktrGzEUhYeSQhO3u_4AQaF0Ebt6jEbjVTFDmrgkuPSxFporja2gkRxppo9_X01tSlyCFhLSuR_n6p6L4swHb4riNcELSkrxfv3p-m7xtaRYEP6sOCdE1HOBRXn26PyiuEjpHuOqqgg7Lx5u7HaHrn7to0nJBo9Ch-42XxqKbEKrlAJYNRiNftphhz6HEFHjrLegHNqMA4TeJKS8Ruu-H71Ba99ZN8RckpD1qAkuI1fa-AAqgvWhVy-L551yybw67rPi-8erb83N_HZzvW5Wt3MoeTXMGWggYCqsWqIJVEaTJQeBgQvCGMOUC8o6wrjuAJuy4rWgAnfatLpUXJRsVqwPXB3UvdxH26v4WwZl5d-LELdSxcGCM7JlbYfrlmoFulxCV-eD4KpaMsqJwjyzPhxY-7HtjQbjc4_uBHr64u1ObsMPSTAXguafnhXvjoQYHkaTBtnbBMY55U0Yk6S1qAWhmE_G3xykW5W9Wd-FjIRJLldCMFZjJiZLiydUeWnTW8i5yIMwpwVvHxXsjHLDLgU3Dnnq6VR4eRBCDClF0_3rk2A55UxOOZPHnGU5_U8OdlATNRuy7umiP59f1x4 |
CitedBy_id | crossref_primary_10_1097_MD_0000000000039299 crossref_primary_10_1007_s12032_024_02464_9 crossref_primary_10_1016_j_mocell_2024_100166 |
Cites_doi | 10.18632/oncotarget.3185 10.1016/j.tranon.2021.101174 10.18632/aging.102003 10.1093/mutage/ger067 10.1159/000495673 10.1016/j.gene.2012.02.011 10.4161/epi.24976 10.3390/antiox8050112 10.1038/s41418-021-00901-0 10.1093/jnci/djz093 10.1186/s13148-019-0642-0 10.1038/sj.bjc.6602589 10.1016/s1470-2045(07)70246-2 10.3748/wjg.v13.i28.3784 10.1016/j.bbamcr.2013.11.012 10.3389/fpls.2017.01720 10.1093/annonc/mdl035 10.1371/journal.pone.0028222 10.1111/cas.13863 10.1136/gut.2004.044214 10.3390/ijms18030567 10.3390/ijms21155311 10.1016/j.ajhg.2020.06.013 10.1038/s41418-018-0259-4 10.1016/j.humpath.2018.03.011 10.1016/s0140-6736(18)30789-x 10.18632/oncotarget.18556 10.1038/s41575-019-0189-8 10.1016/j.celrep.2012.11.018 10.1155/2018/2397863 10.18632/oncotarget.3889 10.1007/s12551-021-00812-x 10.1016/j.canlet.2013.11.011 10.1111/ene.13360 10.1002/humu.10175 10.3748/wjg.v24.i22 10.1016/j.critrevonc.2019.01.023 10.1002/ar.21119 10.3892/ijo.2018.4333 10.1016/j.mam.2019.06.002 10.1016/j.intimp.2020.107041 10.1016/j.bbadis.2018.01.011 10.1038/s41418-018-0095-6 10.1093/bib/bbaa047 10.1038/pj.2016.37 10.1158/0008-5472.CAN-17-1394 10.1093/brain/awv311 10.1093/nar/gkq006 10.1038/bjc.2014.429 10.3748/wjg.v20.i22.6786 10.3390/jcm10112391 10.1016/j.tibs.2003.09.003 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 Dove Medical Press Limited 2023 Zhao et al. 2023 Zhao et al. 2023 Zhao et al. |
Copyright_xml | – notice: COPYRIGHT 2023 Dove Medical Press Limited – notice: 2023 Zhao et al. – notice: 2023 Zhao et al. 2023 Zhao et al. |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.2147/IJGM.S420715 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ: Directory of Open Access Journal (DOAJ) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Zhao et al |
EISSN | 1178-7074 |
EndPage | 4615 |
ExternalDocumentID | oai_doaj_org_article_b3bf08b2dacd49cf8dac75a693251a05 PMC10577261 A773380375 10_2147_IJGM_S420715 |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 0YH 29J 2WC 53G 5GY 5VS 7X7 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IHW IPNFZ ITC KQ8 M2O M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 UKHRP VDV PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c456t-3cdc1ce60ab1d1c6ed195c70c571333025723f135dfc0e46587270fdebd4a5743 |
IEDL.DBID | M48 |
ISSN | 1178-7074 |
IngestDate | Wed Aug 27 01:11:07 EDT 2025 Thu Aug 21 18:35:46 EDT 2025 Fri Jul 11 05:31:39 EDT 2025 Tue Jun 17 22:21:29 EDT 2025 Tue Jun 10 21:13:27 EDT 2025 Thu May 22 21:11:47 EDT 2025 Thu Apr 24 23:04:50 EDT 2025 Tue Jul 01 01:04:40 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | https://creativecommons.org/licenses/by-nc/3.0 This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c456t-3cdc1ce60ab1d1c6ed195c70c571333025723f135dfc0e46587270fdebd4a5743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
ORCID | 0000-0002-3034-1848 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/IJGM.S420715 |
PQID | 2878712054 |
PQPubID | 23479 |
PageCount | 21 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b3bf08b2dacd49cf8dac75a693251a05 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10577261 proquest_miscellaneous_2878712054 gale_infotracmisc_A773380375 gale_infotracacademiconefile_A773380375 gale_healthsolutions_A773380375 crossref_primary_10_2147_IJGM_S420715 crossref_citationtrail_10_2147_IJGM_S420715 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20231031 |
PublicationDateYYYYMMDD | 2023-10-31 |
PublicationDate_xml | – month: 10 year: 2023 text: 20231031 day: 31 |
PublicationDecade | 2020 |
PublicationTitle | International journal of general medicine |
PublicationYear | 2023 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | Giuliani (ref40) 2019; 8 Li (ref7) 2013; 8 Naccarati (ref44) 2012; 27 Marcuello (ref19) 2019; 69 Manning (ref8) 2003; 28 Pagès (ref53) 2018; 391 Guillen Sacoto (ref42) 2020; 107 Wang (ref23) 2010; 293 Zhang (ref12) 2015; 6 Sevilla (ref26) 2016; 139 Worthley (ref45) 2007; 13 Pan (ref24) 2018; 53 Xi (ref1) 2021; 14 Liu (ref43) 2022 Buccafusca (ref3) 2019; 136 Liao (ref33) 2019; 11 Ciccolallo (ref38) 2005; 54 Tong (ref32) 2018; 1864 Liu (ref36) 2019; 110 Sun (ref50) 2020; 8 Ando (ref41) 2017; 24 Franke (ref6) 2019; 111 Wang (ref35) 2018; 25 Li (ref9) 2012; 2 Lukaszewicz-Zajac (ref15) 2021; 10 Keum (ref5) 2019; 16 Koch (ref25) 2017; 8 Sanchez-Solana (ref29) 2014; 1843 Zhang (ref27) 2018; 78 Binefa (ref37) 2014; 20 Liu (ref30) 2019; 26 Pellino (ref18) 2018; 2018 Iacopetta (ref49) 2006; 17 Tuupanen (ref13) 2014; 111 Jin (ref21) 2020; 89 Iacopetta (ref48) 2003; 21 Mármol (ref4) 2017; 18 Wang (ref11) 2015; 6 Villéger (ref2) 2018; 24 Zhang (ref17) 2014; 345 Kim (ref52) 2016; 48 Chen (ref14) 2011; 6 Zhou (ref51) 2021; 22 Ding (ref10) 2018; 76 Shao (ref22) 2010; 38 Liao (ref28) 2017; 8 Verdecchia (ref39) 2007; 8 Guddeti (ref31) 2021; 13 Liu (ref34) 2018; 51 Han (ref16) 2019; 11 Lopez (ref47) 2012; 499 Ogunwobi (ref20) 2020; 21 Smith (ref46) 2005; 92 |
References_xml | – volume: 6 start-page: 9877 year: 2015 ident: ref11 publication-title: Oncotarget doi: 10.18632/oncotarget.3185 – volume: 14 start-page: 101174 year: 2021 ident: ref1 publication-title: Transl Oncol doi: 10.1016/j.tranon.2021.101174 – volume: 11 start-page: 3639 year: 2019 ident: ref33 publication-title: Aging doi: 10.18632/aging.102003 – volume: 27 start-page: 211 year: 2012 ident: ref44 publication-title: Mutagenesis doi: 10.1093/mutage/ger067 – volume: 51 start-page: 1679 year: 2018 ident: ref34 publication-title: Cell Physiol Biochem doi: 10.1159/000495673 – volume: 499 start-page: 81 year: 2012 ident: ref47 publication-title: Gene doi: 10.1016/j.gene.2012.02.011 – volume: 8 start-page: 685 year: 2013 ident: ref7 publication-title: Epigenetics doi: 10.4161/epi.24976 – volume: 8 start-page: 79 year: 2019 ident: ref40 publication-title: Antioxidants doi: 10.3390/antiox8050112 – year: 2022 ident: ref43 publication-title: Cell Death Differ doi: 10.1038/s41418-021-00901-0 – volume: 111 start-page: 1131 year: 2019 ident: ref6 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djz093 – volume: 11 start-page: 51 year: 2019 ident: ref16 publication-title: Clin Epigenetics doi: 10.1186/s13148-019-0642-0 – volume: 92 start-page: 1813 year: 2005 ident: ref46 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602589 – volume: 8 start-page: 784 year: 2007 ident: ref39 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(07)70246-2 – volume: 8 start-page: 34 year: 2020 ident: ref50 publication-title: J Immunother Cancer – volume: 13 start-page: 3784 year: 2007 ident: ref45 publication-title: World J Gastroenterol doi: 10.3748/wjg.v13.i28.3784 – volume: 1843 start-page: 316 year: 2014 ident: ref29 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamcr.2013.11.012 – volume: 8 start-page: 1720 year: 2017 ident: ref25 publication-title: Front Plant Sci doi: 10.3389/fpls.2017.01720 – volume: 17 start-page: 842 year: 2006 ident: ref49 publication-title: Ann Oncol doi: 10.1093/annonc/mdl035 – volume: 6 start-page: e28222 year: 2011 ident: ref14 publication-title: PLoS One doi: 10.1371/journal.pone.0028222 – volume: 110 start-page: 135 year: 2019 ident: ref36 publication-title: Cancer Sci doi: 10.1111/cas.13863 – volume: 54 start-page: 268 year: 2005 ident: ref38 publication-title: Gut doi: 10.1136/gut.2004.044214 – volume: 18 start-page: 567 year: 2017 ident: ref4 publication-title: Int J Mol Sci doi: 10.3390/ijms18030567 – volume: 21 year: 2020 ident: ref20 publication-title: Int J Mol Sci doi: 10.3390/ijms21155311 – volume: 107 start-page: 352 year: 2020 ident: ref42 publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2020.06.013 – volume: 26 start-page: 1905 year: 2019 ident: ref30 publication-title: Cell Death Differ doi: 10.1038/s41418-018-0259-4 – volume: 76 start-page: 58 year: 2018 ident: ref10 publication-title: Hum Pathol doi: 10.1016/j.humpath.2018.03.011 – volume: 391 start-page: 2128 year: 2018 ident: ref53 publication-title: Lancet doi: 10.1016/s0140-6736(18)30789-x – volume: 8 start-page: 97941 year: 2017 ident: ref28 publication-title: Oncotarget doi: 10.18632/oncotarget.18556 – volume: 16 start-page: 713 year: 2019 ident: ref5 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-019-0189-8 – volume: 2 start-page: 1657 year: 2012 ident: ref9 publication-title: Cell Rep doi: 10.1016/j.celrep.2012.11.018 – volume: 2018 start-page: 2397863 year: 2018 ident: ref18 publication-title: Gastroenterol Res Pract doi: 10.1155/2018/2397863 – volume: 6 start-page: 16461 year: 2015 ident: ref12 publication-title: Oncotarget doi: 10.18632/oncotarget.3889 – volume: 13 start-page: 507 year: 2021 ident: ref31 publication-title: Biophys Rev doi: 10.1007/s12551-021-00812-x – volume: 345 start-page: 17 year: 2014 ident: ref17 publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.11.011 – volume: 24 start-page: 1274 year: 2017 ident: ref41 publication-title: Eur J Neurol doi: 10.1111/ene.13360 – volume: 21 start-page: 271 year: 2003 ident: ref48 publication-title: Hum Mutat doi: 10.1002/humu.10175 – volume: 24 start-page: 2327 year: 2018 ident: ref2 publication-title: World J Gastroenterol doi: 10.3748/wjg.v24.i22 – volume: 136 start-page: 20 year: 2019 ident: ref3 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2019.01.023 – volume: 293 start-page: 1002 year: 2010 ident: ref23 publication-title: Anat Rec doi: 10.1002/ar.21119 – volume: 53 start-page: 59 year: 2018 ident: ref24 publication-title: Int J Oncol doi: 10.3892/ijo.2018.4333 – volume: 69 start-page: 107 year: 2019 ident: ref19 publication-title: Mol Aspects Med doi: 10.1016/j.mam.2019.06.002 – volume: 89 start-page: 107041 year: 2020 ident: ref21 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.107041 – volume: 1864 start-page: 1104 year: 2018 ident: ref32 publication-title: Biochim Biophys Acta Mol Basis Dis doi: 10.1016/j.bbadis.2018.01.011 – volume: 25 start-page: 2086 year: 2018 ident: ref35 publication-title: Cell Death Differ doi: 10.1038/s41418-018-0095-6 – volume: 22 year: 2021 ident: ref51 publication-title: Brief Bioinform doi: 10.1093/bib/bbaa047 – volume: 48 start-page: 829 year: 2016 ident: ref52 publication-title: Polymer Journal doi: 10.1038/pj.2016.37 – volume: 78 start-page: 5780 year: 2018 ident: ref27 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-1394 – volume: 139 start-page: 62 year: 2016 ident: ref26 publication-title: Brain doi: 10.1093/brain/awv311 – volume: 38 start-page: 2813 year: 2010 ident: ref22 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkq006 – volume: 111 start-page: 1657 year: 2014 ident: ref13 publication-title: Br J Cancer doi: 10.1038/bjc.2014.429 – volume: 20 start-page: 6786 year: 2014 ident: ref37 publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i22.6786 – volume: 10 start-page: 567 year: 2021 ident: ref15 publication-title: J Clin Med doi: 10.3390/jcm10112391 – volume: 28 start-page: 573 year: 2003 ident: ref8 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2003.09.003 |
SSID | ssj0066613 |
Score | 2.3095524 |
Snippet | Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many... Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies.... Peizhuang Zhao,* Jiajia Ning,* Jun Huang,* Binqian Wei, Zhen Wang, Xue Huang Department of Geriatrics and Gastroenterology, the First Affiliated Hospital of... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 4595 |
SubjectTerms | Adenocarcinoma B cells biomarker Cancer Cancer patients Chromatin colon adenocarcinoma Colon cancer Development and progression diagnosis Gene expression Genes Genetic aspects Genomes Genomics immune cell infiltration Immunotherapy Killer cells morc2 Original Research Patient outcomes Prognosis |
SummonAdditionalLinks | – databaseName: DOAJ: Directory of Open Access Journal (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yB_Eirg9sXTWC4kHaTdLv4zjsurMwrqgLewt54sCYducB_nyrOplhWxEv3ppOQadTVamvuitfEfLKM123Bvu7tNrnZce7vK28zxXrWOdqzyPFxvxjfXZZnl9VVzdafWFNWKQHjgt3rAvtWauFVcaWnfEtXDSVqgF3VFxF9lKIebtkKu7BgMl5EcvcsQ_P8ez8w_zdl1JAPK1GAWjg6f9zN_69QvJGyDm9R-4mrEgncY6H5JYL98ntefob_oBcY5EGPfmZalkD7T2dX3yeCrpY0926O0vxWyv91PcrmlhAl_RiuwFTc2uqgqUzPCPi6Cz4xXIgq13TRaBT2BYDncC-BOFuBU_sv6uH5PL05Ov0LE8tFHIDyGiTF8YablzNlOaWm9pZ3lWmYabC5LQAwNOIwvOist4wVwIcATzDvHXalqoCdPGIHIQ-uMeEtloJWwtflxoc37Gu8a1qvPC2cM51KiNvd-sqTeIXxzYXSwl5BmpBohZk0kJGXu-lf0Rejb_IvUcV7WWQDXu4ATYik43If9lIRl6ggmU8Wrr3aTlpGsjQsQtwRt4MEujVMGmj0uEEeHXkxxpJHo0kwRvNaPjlzogkDmEJW3D9di0hNYXkVABEzkg7sq7Ry41HwuLbQPmN3ZgbSHaf_I_leEruCIBqMQIfkYPNauueAbTa6OeDF_0CgsckBQ priority: 102 providerName: Directory of Open Access Journals |
Title | High Expression of MORC2 is Associated with Poor Clinical Outcomes and Immune Infiltrates in Colon Adenocarcinoma |
URI | https://www.proquest.com/docview/2878712054 https://pubmed.ncbi.nlm.nih.gov/PMC10577261 https://doaj.org/article/b3bf08b2dacd49cf8dac75a693251a05 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZ2kRAviKsojGIkEA8ow87NyQNCXdVtnZRtGlTqW-TrqFQclrTS-PccJ25FGEi8VFV92iY5Pj7fSY6_D6G3hog0k07fJRMmiHOaB1liTMBJTnKdGtpRbBTn6eksPpsn8x20URv1F7D5a2nn9KRm9fLw9ubnZwj4T66Nmcbs4_TspDj8EoeQLZNdtA85iTkRhyLePk8AjN4KJVMKNRODrNm1wN_5di85tRz-d1fqP7snf0tHxw_RA48j8ahz_CO0o-1jdK_wT8qfoBvXwIEnt77P1eLK4OLiahziRYM3PtEKu_uw-LKqauwZQpf4Yr2CaagbzK3CU7d_ROOpNYtlS2Tb4IXFY1gyLR7BmgWpsIZ_rL7zp2h2PPk6Pg28vEIgATWtgkgqSaVOCRdUUZlqRfNEMiITV7hGAIZYGBkaJcpIomOAKoB1iFFaqJgngDyeoT1bWf0c4UzwUKWhSWMBi4ImOTMZZyY0KtJa53yAPmyuayk997iTwFiWUIM4L5TOC6X3wgC921r_6Dg3_mF35Fy0tXFM2e0HVX1d-sArRSQMyUSouFRxLk0Gb1jCU8CtCeUEfuS1c3DZbTvdxns5Ygyqd6cQPEDvWws3B-GgJfcbF-DUHXdWz_KgZwmRKnvDbzaTqHRDrr3N6mrdlFC2QuEaAnweoKw3u3on1x-xi28tHbhTamZQCL_47-N8ie6HgNW6FHyA9lb1Wr8CbLUSQ7TL5myI9o8m55dXw_YOBbyezOmwDahfrkInAA |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+Expression+of+MORC2+is+Associated+with+Poor+Clinical+Outcomes+and+Immune+Infiltrates+in+Colon+Adenocarcinoma&rft.jtitle=International+journal+of+general+medicine&rft.au=Zhao%2C+Peizhuang&rft.au=Ning%2C+Jiajia&rft.au=Huang%2C+Jun&rft.au=Wei%2C+Binqian&rft.date=2023-10-31&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-7074&rft.eissn=1178-7074&rft.volume=16&rft.spage=4595&rft_id=info:doi/10.2147%2FIJGM.S420715&rft.externalDocID=A773380375 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7074&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7074&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7074&client=summon |